Form 4: Crinetics Pharmaceuticals' Chief Scientific Officer Sells Shares Under 10b5-1 Plan

Stephen F. Betz, Chief Scientific Officer of Crinetics Pharmaceuticals, sold 1,035 shares of common stock at an average price of $51.50 per share under a pre-arranged Rule 10b5-1 trading plan.

Summary

• On September 10, 2024, Stephen F. Betz, the Chief Scientific Officer of Crinetics Pharmaceuticals, sold 1,035 shares of the company's common stock.
• The sale was executed automatically under a Rule 10b5-1 trading plan previously adopted by Mr. Betz.
• The shares were sold in open market transactions at a volume weighted average price of $51.50 per share.
• The price range for the sales on that date was between $51.10 and $51.97 per share.
• Following the transaction, Mr. Betz still beneficially owns 68,576 shares of Crinetics Pharmaceuticals' common stock.

Sentiment

Score: 5

Explanation: The sentiment is neutral as the transaction is a routine sale under a pre-arranged trading plan and doesn't necessarily indicate a change in the insider's view of the company's prospects.

Industry Context

Sales by company insiders are a common occurrence and are often pre-planned through Rule 10b5-1 trading plans to avoid accusations of trading on inside information. The market typically analyzes these sales in the context of the company's overall performance and future prospects.

Stakeholder Impact

• The sale could have a minor impact on shareholders if it creates downward pressure on the stock price, although the relatively small number of shares sold suggests the impact will be minimal.

Key Dates